Program
VV913
A development code. Also written as “VV913 4mg group”, “VV913 8mg group” and “VV913 15mg group”.
Its studies are mostly in Premature Ejaculation, led by Vigonvita Life Sciences.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vigonvita Life Sciences | 44 open or running | phase 2since Jul 19, 2026 | Jan 19, 2026 | Dec 31, 2026phase 1 · NCT07565792 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 19, 2026First study: phase 1 study in Healthy VolunteersFirst studyNCT07372703 · 56 planned · China
- Mar 27, 2026Early phase 1 study in Healthy VolunteersNCT07507838 · 24 planned · China
- Apr 27, 2026Phase 1 study in Healthy VolunteersNCT07565792 · 12 planned · China
- Jul 19, 2026Phase 2 study in Premature EjaculationPhase 2 reachedNCT07722780 · 500 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Healthy VolunteersNCT07565792
- Dec 31, 2026Primary completion: early phase 1 study in Healthy VolunteersNCT07507838
- Dec 31, 2027Primary completion: phase 2 study in Premature EjaculationNCT07722780
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07722780Premature Ejaculation · China | 2 | Not yet recruiting | Dec 31, 2027 | 500 |
| NCT07565792Healthy Volunteers · China | 1 | Recruiting | Dec 31, 2026 | 12 |
| NCT07507838Healthy Volunteers · China | Early 1 | Recruiting | Dec 31, 2026 | 24 |
| NCT07372703Healthy Volunteers · China | 1 | Recruiting | Sep 2026 | 56 |
How it is read
Names in the registry
- “VV913”, 3 entries
- “VV913 4mg group”, 2 entries
- “VV913 8mg group”, 2 entries
- “VV913 15mg group”, 2 entries
- “VV913 2mg Capsules”, 1 entry
Codes read as this program: VV913.
Conditions, from the studies’ own filings
- Premature Ejaculation, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.